PULSE BIOSCIENCES, INC. (PLSE) Form 8-K — Sep 15, 2026
Pulse Biosciences entered into an equity distribution agreement with Mizuho Securities USA on September 15, 2026, establishing a new at-the-market offering program under which it may sell up to $85,000,000 of common stock, with Mizuho receiving a commission of up to 3.0% of gross sales. The same 8-K discloses that the Company terminated its prior TD Cowen ATM program on September 14, 2026 with only $1.0 million left unsold, and that 1,379,925 shares worth approximately $68.8 million had already been issued and sold under a separate $75 million ATM established with Mizuho on August 6, 2026.
Key figures
- Gross Proceeds
- 85000000
- Agent commission max
- 3.0%
- New atm capacity usd
- 85000000
- August 2026 atm proceeds
- approximately $68.8 million
- Agent counsel fee cap usd
- 85000
- August 2026 atm shares sold
- 1379925
- August 2026 atm capacity usd
- 75000000
- Td cowen program unsold at termination
- $1.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.